CCS1477
PreclinicalSmall molecule
CCS1477 is one of 15 small molecule programs targeting Haematological Malignancy. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Haematological Malignancy
#DrugCompanyPhaseTrials
1Venclexta
AbbViePreclinical
Ninlaro
TakedaPreclinical
Tecvayli
Johnson & JohnsonPreclinical
Darzalex
Johnson & JohnsonPreclinical
Alecensa
RochePreclinical
Tecentriq
RochePreclinical
Rozlytrek
RochePreclinical
Tabrecta
NovartisPreclinical
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Decadron
AAspen Global Incorporated
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CCS1477. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- CCellCentric Ltd.